Urogen Pharma (URGN) News Today $14.24 -0.40 (-2.73%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$14.22 -0.02 (-0.11%) As of 07/11/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmJuly 11 at 10:42 AM | globenewswire.comUroGen Pharma Shows Market Leadership With Jump To 81 RS RatingJuly 11 at 4:42 AM | msn.comUrogen Pharma's (URGN) Buy Rating Reiterated at HC WainwrightJuly 11 at 2:11 AM | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Receives "Buy" Rating from HC WainwrightJuly 8, 2025 | marketbeat.comUroGen Pharma’s Promising Outlook: Buy Rating Backed by Clinical Success and FDA ApprovalsJuly 8, 2025 | tipranks.comUrogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral CapitalJuly 8, 2025 | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Earns Buy Rating from D. Boral CapitalJuly 7, 2025 | marketbeat.comUroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerJuly 7, 2025 | globenewswire.comUroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder CancerJuly 6, 2025 | msn.comHarel Insurance Investments & Financial Services Ltd. Cuts Position in Urogen Pharma (NASDAQ:URGN)July 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNJuly 2, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNJuly 1, 2025 | globenewswire.comURGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for InformationJune 30, 2025 | globenewswire.comURGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 30, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 27, 2025 | prnewswire.comUrogen Pharma (NASDAQ:URGN) Trading Down 5.3% - Time to Sell?June 24, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by BrokeragesJune 24, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 23, 2025 | globenewswire.comLowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen†or the “Companyâ€) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmJune 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 22, 2025 | prnewswire.comStocks With Rising Relative Price Strength: UroGen PharmaJune 20, 2025 | msn.comUrogen Pharma (NASDAQ:URGN) Trading 10.3% Higher - Here's What HappenedJune 18, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 18, 2025 | globenewswire.comHC Wainwright Decreases Earnings Estimates for Urogen PharmaJune 18, 2025 | marketbeat.comH.C. Wainwright Sees Billion Dollar Potential in UroGen’s New TherapyJune 17, 2025 | msn.comUroGen Pharma (NASDAQ:URGN) Trading Down 7.7% - Time to Sell?June 17, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 17, 2025 | prnewswire.comUroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in MayJune 17, 2025 | marketbeat.comInvestors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGNJune 16, 2025 | globenewswire.comUroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst UpgradeJune 16, 2025 | marketbeat.comURGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law FirmJune 16, 2025 | prnewswire.comUroGen Pharma (NASDAQ:URGN) Stock Rating Upgraded by HC WainwrightJune 16, 2025 | marketbeat.comURGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)June 16, 2025 | globenewswire.comUROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UroGen Pharma Ltd.June 16, 2025 | globenewswire.comUroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. ...June 16, 2025 | gurufocus.comUroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd.June 16, 2025 | prnewswire.comSG Americas Securities LLC Buys 142,245 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)June 16, 2025 | marketbeat.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGenJune 15, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNJune 15, 2025 | globenewswire.comURGN SHAREHOLDERS: UroGen Pharma Ltd. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 28 Deadline (NASDAQ:URGN)June 14, 2025 | globenewswire.comFDA approves UroGen’s Zusduri for non-muscle invasive bladder cancerJune 13, 2025 | yahoo.comUroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20June 13, 2025 | msn.comScotiabank Forecasts Strong Price Appreciation for UroGen Pharma (NASDAQ:URGN) StockJune 13, 2025 | marketbeat.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGNJune 13, 2025 | globenewswire.comUroGen Pharma: Lessons Learned And Future OutlookJune 13, 2025 | seekingalpha.comUroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens BermanJune 13, 2025 | globenewswire.comUroGen Pharma (NASDAQ:URGN) Shares Gap Up Following Analyst UpgradeJune 13, 2025 | marketbeat.comGuggenheim Forecasts Strong Price Appreciation for UroGen Pharma (NASDAQ:URGN) StockJune 13, 2025 | marketbeat.comUroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGNJune 13, 2025 | prnewswire.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGenJune 12, 2025 | globenewswire.com Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.460.99▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼127▲URGN Articles Average Week Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mirum Pharmaceuticals News Today ImmunityBio News Today Arrowhead Pharmaceuticals News Today Apellis Pharmaceuticals News Today Twist Bioscience News Today NewAmsterdam Pharma News Today Apogee Therapeutics News Today Recursion Pharmaceuticals News Today Denali Therapeutics News Today Indivior News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free URGN Stock Alerts